Expands Global Footprint with Strategic Partnership in India

Open PDF
Stock RNV.ASX (RNV.ASX)
Release Time 10 Apr 2025, 9:29 a.m.
Price Sensitive Yes
 ReNerve Expands Global Footprint with Strategic Partnership in India
Key Points
  • Formed strategic partnership with NetCentrix Ventures to enter high-growth Indian nerve repair market
  • Indian nerve repair market valued at US$115M, projected to reach US$270M+ by 2030
  • Partnership to focus on regulatory approval and commercialization of ReNerve's NervAlign® Nerve Cuff
Full Summary

ReNerve Limited (ASX:RNV), an innovative Australian medical device developer specialising in advanced peripheral nerve repair technologies, has announced a partnership agreement with NetCentrix Ventures to establish and develop operations in the Indian healthcare market. The agreement will initially focus on securing regulatory approval in India for ReNerve's flagship product, the NervAlign® Nerve Cuff, followed by a coordinated commercialisation strategy tailored to the Indian healthcare ecosystem. The Indian nerve repair sector is currently valued at US$115M with an exceptional compound annual growth rate of 18.5%, and is projected to more than double to approximately US$270M+ by the year 2030. India represents a significant growth opportunity in peripheral nerve repair due to factors such as rapidly expanding healthcare infrastructure, increasing investment in advanced surgical capabilities, a substantial and growing middle class with improving access to specialised medical procedures, rising incidence of traumatic nerve injuries, and increased prevalence of diabetes-related nerve conditions. The partnership with NetCentrix Ventures, which has an MoU with BRIC RGCB, an institution of the Biotechnology Research and Innovation Council under the Government of India, provides ReNerve with specialised local expertise and established distribution networks essential for a successful entry into the Indian market.

Guidance

The partnership with NetCentrix Ventures is expected to facilitate the regulatory approval and commercialization of ReNerve's NervAlign® Nerve Cuff product in the Indian market, which is projected to be a high-growth opportunity for the company.

Outlook

ReNerve's strategic partnership in India is part of its global expansion strategy, complementing the company's existing partnerships in Taiwan, Hong Kong, the Middle East, and Mexico, further strengthening its international commercialization framework.